Adherence
n Background
The increasing use of oral agents for cancer therapy has created a new paradigm in cancer care. 1Y3 For the past few years, oral anticancer drug use has accelerated through the oncology community, with additional new oral agents receiving approval and support monthly. As a result, patients must now assume greater responsibility for filling prescriptions from retail and specialty pharmacies and implementing complex dosage regimens in addition to self-monitoring symptoms, side effects, and adverse events. 3Y6 Patients may take 5 to 12 pills 2 to 3 times daily with confusing schedules such as 2 weeks on and 1 week off only to be followed by 2 more weeks on. In most cases, patients are prescribed with these drugs for extended periods, and in some instances, these agents may be prescribed for the rest of the patient's life. This new treatment paradigm shifts delivery of chemotherapy from a safe and controlled process monitored on a regular basis by oncologists and oncology nurses in hospital units or outpatient-infusion clinics to patients' homes where dosage, management of symptoms, and adverse effects become the responsibility of patients and their families. Cancer patients on oral agents indicate that often, they self-titrate doses, thus not adhering to prescribed regimens to tolerate adverse effects that include peripheral neuropathy, pain in hands and feet, and diarrhea. 7 The disconnect between what the patient receives and the clinicians' assumptions that the patient is taking the dose as prescribed may result in the clinicians changing the dose or agent because they believe that the patient is nonresponsive to the treatment or having unexpected side effects. 3, 8 The relationship between management of symptoms and adherence to oral agents among cancer patients is a particularly difficult treatment dilemma. Compounding this relationship is the influence of a patient's beliefs about oral chemotherapeutic medicines. 9 The more adherent the patients are to oral agents, the more symptoms they are likely to experience. As a result, prompt and aggressive management of symptoms may be crucial to future adherence. Strategies must be developed to determine if improved management of symptoms can lead to an increase in adherence to oral agents. Interventions are needed that acknowledge costs, beliefs about medicines, and numbers of pills to be taken, which may represent important factors contributing to adherence. 1Y3,10,11 There are relatively few studies seeking to determine if patient adherence could be improved by reducing severity of symptoms and side effects thought to be related to certain medications. 12 This team has demonstrated how to deliver symptom management strategies 13Y19 specifically using an automated voice response (AVR) system for symptom management. 20, 21 The results of the AVR studies indicate that the system is not only feasible in the management of symptoms with cancer patients, it is also more effective than nurse-delivered interventions based on cognitive behavioral approaches. 20 This pilot study attempted to assess the feasibility of accruing cancer patients who are undergoing nonhormonal, oral chemotherapeutic agent treatment to encourage their participation in a research project designed to develop and test an AVR system. In addition, the pilot study would assess adherence and offer patients symptom management strategies via a symptom management guide and nursing calls to patients. This study was guided by 3 questions: (1) Can a patient be monitored for adherence to oral chemotherapeutic agents? (2) Can adherence be improved by an AVR system and an intervention nurse where both address symptom management and adherence? (3) Can this be demonstrated by an observed association between symptom management and improved patient adherence?
The scientific method used in the pilot study was a modified health belief model 22 approach to patient adherence, which builds upon a cognitive behavioral intervention framework for symptom management. 14,17,23Y25 The concepts and their relationships are summarized in Figure 1 .
n Methods
Setting/Sample
The institutional review board of the sponsoring university approved this research. Accrual of patients for this pilot study occurred at a National Cancer Institute Community Clinical Oncology Programs clinical site and a university-based cancer clinic located in Michigan. Participants were entered in the study between September 2007 and January 2008. Thirty participants who had solid tumor cancer diagnoses including breast, colon, and lung cancers and were on nonhormonal, oral chemotherapeutic agents enrolled in this longitudinal descriptive pilot study. To be eligible, participants should have a touch-tone phone, no hearing deficits that might interfere with telephone use, good English language comprehension, and no cognitive deficits as evaluated by an on-site nurse. They must also agree to have their medical records and specialty pharmacy records audited in addition to completing 8 automated telephone contacts requesting information on symptom severity and medication adherence. Other telephone contacts for nurse interventions for management of severity of symptoms and adherence to oral chemotherapeutic agents might be necessary as well. Excluded were those who had been diagnosed with an emotional or psychological disorder under the care of a psychiatrist or a psychologist.
This pilot study commenced with trained nurse recruiters identifying participants and providing detailed information about the study, including answering any questions before completing and signing an informed consent form. The nurse recruiter explained to each individual that he/she would be receiving a telephone call from an experienced interviewer within a week (intake interview) and again in 10 weeks (exit interview). These interviews would be geared toward retrieving information such as adherence to his/her oral chemotherapy pills, sociodemographic data, health conditions, and symptoms that he/she may be experiencing. The automated system was further explained in detail, including asking the participant to pick a day and time for contact and a preferred telephone number. Participants were discouraged from using cellular phones, keeping in mind that the study could consume valuable minutes of their cell time. It was further explained that the automated system would call at the prearranged time each week. If there was no answer, the telephone system would call again in 40 minutes and then again 40 minutes later. If there was no answer that day or the telephone was answered but the participant was unavailable, the system would call again the next day at the same prearranged time repeating the call 2 more times every 40 minutes if necessary. If there was no answer or the participant was unable to accept the call during the second week, the system would contact the sponsoring university and someone would contact the participant. And finally, before leaving the clinic, all enrolled participants were given a copy and an introduction to the Symptom Management Toolkit (SMT) from the nurse recruiter, as well as copies of all their signed enrollment documents. This guide offered evidence-based interventions for the management of each of the 15 symptoms that were part of this study. All interventions focused on self-care activities that patients could implement and indicated how they could engage family members to assist them, along with recommendations as to how and when to report each symptom to their oncologist.
Instruments and Measures
The following are the instruments and measures assessed at the intake and exit interviews: AVR weekly calls, medical record audit, and a pharmacy review. In this pilot study, we did not attempt to report reliability measures for measures that were not related to the assessment of some larger, latent construct as the instruments and measures used are not appropriate for reliability assessment.
SYMPTOM EXPERIENCE INVENTORY
The cancer symptom inventory, developed by this research team, had been used in previous work. 19, 26 Fifteen prevalent symptoms associated with patients undergoing chemotherapy were examined. Participants were asked if they had experienced each symptom (yes/no) within the prior 7 days, and if so, they were to rate the severity on a 0-to 10-point scale that described the severity of the symptom and to what extent the symptom disrupted or caused limitations in their regular daily activities. This measure was used as an index.
DEPRESSION
The Center for Epidemiologic Studies Depression Scale-20 (CESD-20) depression scale is a widely used measure of depressive affect for nonpsychiatric populations. 27, 28 This measure has established psychometric properties (coefficient ! of .89). 26 
SHORT FORM-12
The Short Form-12 (SF-12) functional ability scale is a widely used measure of an individual's ability to function. This measure has sound psychometric properties (! of .92) in this research.
UTILIZATION AND SERVICES
The study focused on the use of increased physician oncology visits, hospitalizations, and emergency department visits during the study time period (8 weeks). These measures were used as indices.
OUT-OF-POCKET COSTS
At intake and 10 weeks, participants were asked how much they paid out-of-pocket (OOP) for their oral chemotherapy agents. These costs were then prorated over the numbers of pills purchased. The cost of the drugs was obtained from the pharmacies and co-payments were determined for each oral agent. Costs were also used as an index.
ADHERENCE WITH ORAL AGENTS
Participant adherence to their oral chemotherapeutic agents was measured from multiple perspectives. Medical record audits were performed at the time the participant consented (identify site of cancer, stage, name of oral agent, number of pills prescribed per day, their frequency, and quantity taken for each dose, as well as the interval between doses) and again at the end of the study (change in dose, pills per day, intervals and dose delays, stoppages, and the dates of each). Participant reports of adherence were obtained from the intake and 10-week interviews and at each of the 8 AVR calls. During the intake and 10-week interviews, participants were asked to identify the name of their oral agent, number of pills to be taken in AM and PM, and the number of days or weeks on and off their pills per month or cycle. At each weekly AVR call, the system asked the number of pills that the participant took in the past 7 days. If the participant reported a number different than initially programmed, the nurse intervener was sent an e-mail notifying her of a discrepancy.
SPECIALTY AND REGULAR PHARMACY REPORT
After the 10-week interview, the participant's pharmacy was contacted and a report was requested with fill and refill information for the oral chemotherapeutic agents, specifically detailing the number of pills dispensed to the participant during the study.
CALCULATION OF ADHERENCE MEASURES
The nurse intervener made a comparison of the information from intake audit with data collected during the intake interview on medications to assess the baseline level of adherence. This note was placed in the electronic intervention file for each participant and anchored decisions regarding each participant's adherence at subsequent calls. After each weekly call, participants reporting pill counts less or more than those originally prescribed received a call from the nurse intervener to discuss nonadherence and to provide an intervention when needed. If the participant reported a dose adjustment by the oncologist, the nurse would determine the reason for the adjustment and, if due to a symptom, would assist the participant to manage the symptom. At that point, the intervention would be logged as symptom assistance.
At the end of the 10-week study, an on-site nurse recruiter audited the medical chart; recorded any dose changes, delays, reductions, stoppages, and toxic side effects; and provided the audit results to the university. This information was compared as follows: (1) weekly AVR patient reports of pill counts with the dose from the medical record adjusted for delays, interruptions, and stoppages; (2) intake and 10-week interview data were paired with the record data on dosage and changes as of the date of the interview; (3) every indicator was paired at each time point against the availability of pills to the participant based upon the prescriptions filled and number of pills obtained per script. Through these measures, the pilot study collected a vast array of adherence measures for each participant. As indicated in previous studies, it is important to use more than one method to measure adherence. 29 
PARTICIPANT ACCEPTABILITY AND SATISFACTION
Participant acceptability of the intervention was measured by the number of AVR calls missed that were not related to hos-pitalization or poor health. Telephone hang-ups were counted as well in the course of the AVR script when they occurredV symptom management or adherence. Second, acceptability was assessed by the proportion of nurse calls accepted and completed for management of symptoms and for assistance with adherence (nurse-related acceptance). Satisfaction with the AVR system and SMT was measured using a short satisfaction instrument designed especially to capture patients' level of satisfaction with the AVR system used in the previous RCT. A series of satisfaction items describing dimensions of patients' satisfaction with the nurse calls were used to examine adherence. This satisfaction measure was used in a previous trial of the AVR. Psychometrics for this instrument was found to be acceptable (! greater than .65) as assessed during the course of the pilot study.
Procedures
The pilot study began with trained nurse recruiters from each clinical site identifying participants and explaining the study. Nurse recruiters were provided a nurse recruiter manual, which contained detailed information on the pilot study and the nurses' responsibilities. The authors met with the nurse recruiters to provide on-site training on how to screen for eligible participants and how to proceed with the registration process. Nurse recruiters from each site were familiar with the clinical trials process. All enrolled participants received a copy of the SMT from the nurse recruiter before leaving the clinic. Enrolled participants then received an intake interview, 8 AVR calls, an exit interview, and nurse intervention calls when the AVR system indicated nonadherence and/or symptom severity of more than or equal to 4 for 3 consecutive weeks.
Interviews
Intake and exit interviews were conducted by knowledgeable interviewers experienced in prior studies using the AVR system for symptom management with cancer patients. Interviewers were provided with a study interviewer manual on conducting interviews and were asked to audio tape a percentage of interviews. Participants were informed of the request to audio tape the interviews in the consent form and had the option of refusing. The taped sessions were reviewed by the authors for reliability between interviewers and to ensure that the questions were asked as intended. Interviewers entered the participant's responses directly into a Computer-Assisted Telephone Interview System. Sociodemographic information was collected on the intake interview. Participant intake and exit interviews included measurements of adherence, compliance with oral medications, health conditions, symptoms, CESD, SF-12, and service utilization.
The study participants received 8 weekly calls from the AVR system to assess the severity of 15 symptoms and oral chemotherapy agent adherence. At each contact, participants were asked to enter their personal identity number (PIN) for identification. If the PIN was incorrect or forgotten, then someone from the staff called the participants and reminded them of their PIN so that calls could take place. At the first and all subsequent calls, participants were asked about the number of oral cancer pills they were prescribed and had actually taken in the past week. Participants were then queried as to the severity of each of the 15 symptoms, asking them to indicate on a scale from 0 (not present) to 10 (worst severity possible) how severe the current symptom was. At the end of the call, the system indicated the symptoms that participants identified with a severity of 4 or higher and asked them to read those sections of the SMT for each symptom. Subsequent calls began with questions on the number of pills taken followed by a review of those symptoms scored 4 or higher at the previous session. If the participant had indicated that a symptom scored 4 or higher was a problem, the voice would state the symptom and ask if the participant was able to read the information in the SMT. If the participants replied positively that they had used the SMT for information, the voice would inquire as to how helpful the information had been for managing the symptom.
Nursing Interventions
Study participants reporting symptom severity at their weekly AVR calls were encouraged to use the SMT. In addition, if the study participant reported anything less than 100% adherence through weekly AVR calls or severity of one or more symptoms at more than 4 for 3 consecutive weeks, a specially trained nurse contacted the participant by telephone to confirm nonadherence and/or provide evidence-based nursing intervention for adherence and/or management of symptoms. The domains for the nursing interventions used by the specially trained nurse for symptom management include fostering self-care behaviors, providing information about oral agents, problem solving for symptoms or adherence, providing support, coaching and counseling, communicating with providers, and decision making, all to enhance tailored symptom management and adherence behaviors. Based on the assessment, the nurse provided intervention strategies to assist the participant to deal with adherence problems and to try additional strategies for resistant symptoms. All strategies recommended were documented, and success for each was evaluated at the following contact.
n Results This pilot study examined the ability to monitor patients for adherence to oral chemotherapeutic agents, using an AVR program and a nurse-administered telephone intervention to reduce symptom severity among advanced cancer patients undergoing oral chemotherapy.
Attrition Rate
A total of 30 patients agreed to participate in the study, signed informed consents, and completed the recruitment process.
Six participants withdrew before completing all 8 AVR calls, and 2 participants withdrew after all 8 AVR calls were completed but before the exit interview as shown in Table 1 . Two participants were withdrawn because of death, one transferred to a hospice, two developed confusion due to brain metastasis and radiation therapy and were no longer able to answer questions, one participant withdrew because of a busy schedule, one refused after having multiple calls at midnight, and one withdrew for unknown reasons.
Sociodemographic Characteristics
The sociodemographics of the sample are presented in Table 2 . The mean (SD) age of the participants was 59.93 (12.03) years, and 94% were female. Sixty-three percent of the participants had some college education, 90% were white, and 80% were married. Breast cancer was the most common diagnosis, and 77.67% were on a single oral chemotherapeutic agent with varied lengths of time from 1 to 8 months. No significant differences between the adherent and nonadherent groups at baseline were found for sex, age, race, or ethnicity, education, marital status, or type of cancer, and in some instances, the sample size was too small to test equivalency.
Nonadherence
The percentage of missed pills was calculated weekly using the number of pills confirmed divided by the number of pills prescribed. Anything less than 100% adherence was considered nonadherent. Seven of 30 study participants, or 23%, had confirmed nonadherence over the 8-week study period. The most commonly reported reason for nonadherence was ''forgot'' to take the pills, which occurred with 5 participants. One participant could not identify a reason for nonadherence. Six of the nonadherent participants missed a dose one time out of the 8 weeks, or 13% of the time they missed their full number of prescribed pills. One participant missed the full number of prescribed pills for 4 of 8 weeks, or 50% of the time. The 6 participants who missed pills reportedly took between 86% and 93% of their weekly pills. The participant who missed pills for 4 of 8 weeks reported taking 90% of the prescribed pills on average. 
Association Between Symptom Management and Nonadherence
To check the effect of symptom management, we used paired t tests to see how symptom severity changed before and after AVR intervention. Sum of symptom severity at intake was treated as symptom severity before intervention and at exit after intervention. Overall for 22 participants who finished intake, AVR intervention, and the exit interview, their average sum of symptom severity decreased by 4.35, with P value of .21 (which is not a significant difference between symptom severity before AVR intervention and after AVR intervention). When we compared the symptom severity before intervention and after intervention for those who stayed in the pilot study by their adherence status, there existed a marginal decrease in severity for nonadherence (P = .04) as shown in Table 3 .
Association Between Number of Oral Agents and Adherence
To understand if 2 oral agents influence nonadherence more than 1 oral agent does, a comparison was conducted (Table 4) . Seventy-seven percent of the study participants were on 1 oral agent, and 23% were on 2 oral agents. Seventeen study participants, or 57%, were on concurrent intravenous chemotherapy. Seventy-five percent were adherent on single oral agent compared with 86% of the participants who were on 2 oral agents. In addition, 8 study participants, or 27%, discontinued their oral agents with physician's orders sometime during the study. Five study participants, or 17%, had a physician initiate a dosage change (increase or decrease in dosage).
Utilization of Services
Utilization of services focused on the use of increased physician oncology visits, hospitalizations, and emergency department visits during the study time period. During the study, 4 participants were admitted to the hospital for one admission each. One participant had an emergency department visit for a problem unrelated to the chemotherapy. Eight participants had primary care visits, with 6 of them having onetime primary care visits and 1 having 3 primary care visits and 1 receiving home healthcare services. One participant reported not having a primary care physician. No differences were found between adherent and nonadherent participants according to emergency department visits or admissions to hospital.
Functional Ability
The analysis conducted to examine each of the SF-12 items compared the adherence group (n = 23) to the nonadherence group (n =7). T test P values for each of the questions were used to compare the adherence group to the nonadherence group and were each individually more than 0.05, which was not significant.
Depression Assessment
The participants who were in the adherence group had lower mean intake interview CESD scores than the nonadherence group (from 10.91 to 13.13, respectively). The participants in the adherence group had lower mean exit interview CESD mean scores than the nonadherence group (from 8.67 to 11.0, respectively). A comparison between adherent and nonadherent groups at intake and at exit interviews revealed no differences.
Out-of-Pocket Expense
A review of the cost of paying OOP for oral chemotherapy pills was examined in the adherence and nonadherence groups. The average amount spent each time participants filled their prescription for the nonadherence group was $22.14, with an SD of $17.29 and a range from $0 to $40.00. For the adherence group, the mean was $39.06, with an SD of $65.60 and a range from $0 to $254.00. These findings were confirmed by the pharmacy audit. No significance was found for OOP cost for the adherence group as compared to the nonadherence group.
Nurse Interventions
During the pilot study, a specially trained nurse intervener provided patient-centered personalized interventions via telephone calls for participants who had symptom severity of 4 or higher for 3 consecutive weeks and/or for the 7 participants who had adherence of less than 100%. The volume of participants referred to the nurse, as well as the symptom severity and symptom management provided by the nurse, is shown ( Table 5 ). Fatigue and pain were the most frequently occurring symptoms, with symptom severity of more than or equal to 4 for 3 consecutive weeks. Fatigue was an adverse effect of the oral agents that participants were taking while on this study. Other less frequent symptoms warranting nurse intervention included lack of appetite, numbness and tingling, sleep disturbances, and distress, which were also adverse effects from the oral agents.
Satisfaction Questionnaires
Satisfaction questionnaires were administered to all participants after the 10-week survey. Fifty-four percent of the study participants completed the satisfaction questionnaire, for a total of 77% (Table 6 ). Of the 17 participants who completed the satisfaction questionnaire, 12 participants, or 70%, were adherent and 5 participants, or 30%, were nonadherent. Overall, 100% of the participants who completed the survey were either very satisfied or satisfied with the AVR for monitoring symptoms. Of these, 76% used the SMT with a high rate of referral to the appropriate section of the toolkit to manage a symptom. Of those who were contacted by a study nurse, 65% reported help from the nurse with symptoms and 100% reported help from the nurse with nonadherence. In summary, 60% felt that the intervention was helpful, whereas 30% felt that it was both burdensome and helpful and 10% felt that it was not helpful. Of these, 88% would recommend the intervention for symptom management, and 53%, for adherence to medications. Of the 2 participants who were nonadherent and completed the survey, neither felt that it was helpful with promoting adherence to the oral chemotherapy medication and they were nonadherent for reasons of forgetting and missing pills.
n Discussion
The primary aim of this study was to determine the feasibility of monitoring and providing interventions to patients with breast, colon, or lung cancer on nonhormonal chemotherapeutic agents using an AVR system and nurse intervener. The results support such feasibility as the system was easy to use, was easy to learn, and captured the clinical information from patients in their homes.
Most participants experienced symptoms above threshold that were severe enough to generate referral to the SMT and nurse interventions and nonadherence that prompted nurse interventions and an alert to their clinician. The secondary aim of this study was to determine if nonadherence can be defined and measured to examine the relationship between symptom severity and adherence and to compare and contrast the adherent group with the nonadherent group. The data presented here support that contention.
First, and most importantly, nonadherence was defined and measured. Studies indicate that self-report measures, although the most common and easiest to use, have varied concordance when compared with other means of measuring adherence. 30 Self-reporting using the AVR system with follow-up from a study nurse would eliminate some of the inherent hesitancy that a participant might have in admitting nonadherence to the clinicians who prescribed the medication. The participants who reported nonadherence through the AVR were confirmed when reported to the nurse. The research oncology nurse reviewed the enrollment documents before each participant call. The enrollment documents included oral agent information such as a calendar indicating when the participant was to be on and off oral agents. The nurse asked each participant who reported nonadherence why he/she missed his/her pills, and again, as is consistent with other studies, the most common reason for missed doses was forgetfulness. 31 An example of a nursing intervention for a participant who reported forgetfulness as the reason for nonadherence might be the use of implementation intention. 32 The patient imagines taking the pills at the prescribed times and the linking of the initiation of the behavior (pill taking) with cues in the environment such as brushing his/her teeth. For the participant who reported ''out of drug,'' drug unavailability was confirmed through a pharmacy audit. This seemed to be consistent with other studies, where the undersupply of cancer drugs seemed to be as common (14%) as the undersupply of other drugs. 33 In this particular participant, out of drug was a result of the specialty pharmacy not obtaining the drug on time although physician orders were in. The nursing intervention included educating the participant to use a medication calendar and creating a reminder system to ensure that the pills have arrived before the cycle. Second, the AVR system was tested and found to work effectively and efficiently. Automated telecommunication systems have been shown in published studies to improve medication adherence 34 ; however, to our knowledge, this is the first time that the AVR system has been used to explore how it might improve adherence to oral chemotherapeutic agents with cancer patients. We understand that one study showed that simple telephone contacts from the clinician's office by a non-nurse did not significantly improve adherence. 35 However, the structured 8-week AVR system plus individualized nursing calls may more closely mirror the published work of Burke et al 36 and Kim and Oh, 37 with the success of using behavioral interventions for improved adherence.
Results of the measurements on belief of medicines, utilization of services, functional ability status, depression, and OOP medication expense indicate no significant difference between the adherent and nonadherent participants. Most likely, this was a result of the small sample size.
Finally, a beginning exploration of the relationship between symptom severity, adherence, and beliefs about medications occurred. Addressing the barriers to treatment adherence is complex, and most likely, patients have multiple reasons for nonadherence to oral agents. The severity of symptoms from cancer and the side effects of the oral agents may be one of the reasons. Studies of cancer and noncancer diseases indicate that patients decrease adherence as symptoms and medication side effects occur. 31 In this pilot study, no such effect was observed, most likely because of the small sample size.
The findings from this pilot lend continued support to the study framework in that the authors were able to document adherence to oral chemotherapeutic agents, participants accepted the AVR system as a means of recording weekly adherence, over half the participants would recommend the intervention for adherence to medication, and most patients were able to complete the study.
Although it was beyond the scope of this pilot study to evaluate the effectiveness of the AVR system and nurse calls as an intervention to improve adherence to oral chemotherapeutic agents, we did learn from participants that the calls were perceived as ''caring.'' One participant reported that no one at the clinic ever asked her if she was taking her pills, and therefore, she thought she was taking enough when in reality, she had missed 4 doses over the 8-week period. Treatment adherence may be improved if clinicians directly ask patients about their adherence, as well as review the importance of taking oral medications as directed and the possible effect of adherence on their response to treatment. 35, 36, 38, 39 n Limitations
This was a pilot study related to seeking the feasibility of monitoring adherence to oral chemotherapeutic agents and symptoms experienced by cancer survivors often at their thirdand fourth-line cancer treatments, and it has a number of limitations. Monitoring of oral agents through self-report can be misleading, as patients might be more likely to adhere during the study to give the appearance of adherence to their oncologist. The sample size was small and confined primarily to educated white women who had breast cancer and therefore may lend itself to the types of general conclusions that can be formed with nonYbreast-cancer patients and those with other types of oral chemotherapeutic agents. Finally, the recruiting method may have introduced bias because patients who enter into a study with adherence in the title understand immediately that they will be monitored and may have chosen not to enter into the study.
n Provider Implications Future studies on interventions for nonadherence include asking the participants if they are taking their pills exactly as prescribed at each office visit. Perhaps this question will elicit a similar response to that of clinicians asking patients about their smoking cessation. Sometimes, just asking the question at each visit will improve the outcome or, in this case, improve adherence.
The level of satisfaction with and acceptability of the AVR was high. The technique, voice, and duration were acceptable to participants and generally did not pose any technical difficulty. The few technical problems that were encountered were resolved in a timely fashion. Participants offered suggestions on ways to expand and enhance the system that have already been incorporated into future versions.
With these revisions, the next research step that has since been initiated is to test the value of the AVR symptom assessment and management system in improving adherence to oral chemotherapy agents. This study is ongoing and will further evaluate the relationship between symptom management and adherence. Before an electronic system can be incorporated into clinical care, it is essential to demonstrate that these systems are reliable and that they improve care and prove to be cost-effective.
